VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a comprehensive legal drug investigator and formulator service company through Health Canada to produce and supply, for clinical study purposes, psychedelics such as 3,4-methylenedioxymethamphetamine (“MDMA”), GMP grade herbal psilocybin, as well as herbal conditioning product formulations, is pleased to announce the receipt of its herbal fitness product license following a evaluation through the Directorate of Natural Health Products and Over-the-Counter.
Subscribe now to read the latest news in your city and across Canada.
Subscribe now to read the latest news in your city and across Canada.
Create an account or log in to continue your experience.
Don’t have an account? Create an account
Under Segment 29 of the Natural Health Products Regulations, the Expanded Authorization allows for the manufacture, packaging and labeling of herbal fitness products (“NHPs”) at the company’s facility in Princeton, British Columbia.
Get the latest titles and columns.
A welcome email is on the way. If you do not see it, please check your spam folder.
The next factor from Edmonton Journal Headline News will soon be in your inbox.
We found a challenge in their registration. Check back
In addition, the license also provides Optimi with the ability to encapsulate products on site.
“This expands our ability to produce our products on-site for distribution in the global market,” said Optimi CEO Bill Ciprick. “This license allows the company to further diversify and leverage the perspective of its existing manufacturing, processing and packaging functions to streamline execution and reduce prices from its chain of origin to help continued growth. “
Today’s announcement confirms Optimi’s commitment to offering large-scale studies and progression systems at its 10,000 square foot GMP-compliant production facility.
For more information or to schedule an interview, contact Michael Kydd at:
investisseurs@optimihealth. ca902. 880. 6121www. optimihealth. ca
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (ENG: 8BN)
Optimi Health Corp. , a legal end-to-end drug researcher and formulator through Health Canada to produce and supply, for clinical research, psychedelics such as 3,4-methylenedioxymethamphetamine (“MDMA”), GMP-grade herbal psilocybin, as well as functional mushrooms that concentrate on the fitness and wellness markets. Created with the purpose of generating scalable psychedelic formulations for transformative human experiences, the company’s purpose is to be the world’s leading reliable and compassionate drug provider. Optimi’s products are grown and manufactured at its two 20,000-square-foot facility in Princeton, British Columbia.
FORWARD-LOOKING STATEMENTS
This press release comprises forward-looking statements and forward-looking data within the meaning of Canadian securities law (collectively, “forward-looking statements”) that relate to Optimi’s existing expectations and ideals about long-term events, adding to the Company’s ability to to meet its obligations under the Supply Agreement, to meet the Founders’ objectives and earnings schedule for the second quarter of 2023. All statements that explain or imply discussions of expectations, ideals, plans, goals, assumptions or long-term occasions or accomplishment (often, but not always, by using words or words such as “most likely to happen,” “is expected,” “expect,” “will continue,” “is planned,” ” anticipates”, “believes”, “estimates”, “intends”, “plans”, “expects”, “projection”, “strategy”, “target” and “outlook”) are not old facts and would possibly be forward-looking statements and possibly they would involve estimates, assumptions and uncertainties that could also cause actual effects to differ materially from those expressed in such forward-looking statements. There can be no assurance that such expectations will prove to be correct and that undue reliance will not be placed in any of the forward-looking statements included in this press release. These statements speak only as of the date of this press release. In particular, and without limitation, this press release includes forward-looking statements related to the proposed activities to be conducted under the Company’s Health Canada-apturn third-party reseller license and relevant activities similar to psilocybin, psilocin, other psychedelics, some synthetically formulated; and Optimi’s Plans, Focus and Goals.
Forward-looking statements are based on a number of assumptions and are subject to a number of hazards and uncertainties, many of which are beyond Optimi’s control, which may also cause actual effects and timing to differ materially. those disclosed or implied by such statements. forward-looking statements. These dangers and uncertainties include, but are not limited to, the effect and progression of the COVID-19 pandemic and other items set forth under the headings “Forward Looking Statements” and “Risk Factors” in the Company’s Annual Information Form. Company. . Company dated January 9, 2023. Parent and other continuing disclosure documents found on Optimi’s profile at www. sedar. com. Optimi does not assume any legal responsibility to update or revise any forward-looking statements, whether as a result of new information, long-term occasions or otherwise, unless required by law. New points appear from time to time, and Optimi cannot possibly expect all of them or evaluate the effect of each such point or the extent to which any factor, or combination of points, might cause effects particularly different from the contents. in any forward-looking statement.
All forward-looking statements contained in this release are expressly qualified in their entirety by this cautionary statement.
Postmedia is committed to maintaining a civilized discussion forum and encourages all readers to share their views on our articles. Comments can take up to an hour to moderate before appearing on the site. We ask that you keep your comments applicable and respectful. We have enabled email notifications. You will now receive an email if you get a reaction to your comment, if there is an update in a comment thread you adhere to, or if a user adheres to comments. See our network rules for more information and main points on how to adjust your email settings.
365 Bloor Street East, Toronto, ON M4W 3L4
© 2023 Edmonton Journal, a department of Postmedia Network Inc. All rights reserved. Dissemination, unauthorized transmission or is strictly prohibited.
This uses cookies to personalize your content (including ads) and allows us to analyze our traffic. Learn more about cookies here. By continuing to use ourArray, you agree to our Terms of Use and Privacy Policy.